nCounter® Immune Exhaustion Panel
Helping Your Research
Uncover the mechanisms behind T cell, B cell, and NK cell exhaustion in diverse contexts, including cancer and infectious disease, with a 785 gene panel that gets you results in less than 24 hours and is compatible with a broad range of sample types. Characterize immune status, develop signatures for assessing the exhausted state, and identify novel therapeutic targets to prevent or reverse exhaustion.
How It Works
- Directly profile 785 genes across 47 pathways involved in immune exhaustion:
- Immune Activation
- Immune Suppression
- Immune Status
- Immune Checkpoints
- Metabolism & Microenvironment
- Understand the mechanisms of exhaustion in T cells, B cells, NK cells, CAR-T cells and other adoptive immune cells
- Discover novel therapeutic targets for preventing or reversing immune exhaustion
- Determine the extent of a peripherally suppressed, adaptive immune response to cancer with the 18-gene Tumor Inflammation Signature (TIS)
- Quantify the presence and relative abundance of 14 different immune cell types
Chronic infections caused by viruses and other pathogens can induce immune exhaustion. The Human Immune Exhaustion Panel includes probes for Epstein-Barr virus (EBV) and Cytomegalovirus (CMV), and the Mouse Immune Exhaustion Panel includes probes for Lymphocytic Choriomeningitis (LCMV). The panel can be supplemented with up to 55 genes of your choice with a Panel Plus spike-in for studying exhaustion in the context of different types of infectious disease.
The 18-gene Tumor Inflammation Signature (TIS) is included in the panel gene list and measures activity known to be associated with PD-1/PD-L1 inhibitors. Customers have the option to purchase a standalone TIS report with the Immune Exhaustion Panel.
- Includes four axes of biology that characterize a peripherally suppressed, adaptive immune response, including:
- Antigen presenting cells
- T cell/NK cell presence
- IFNγ biology
- T cell exhaustion
- Tissue-of-origin agnostic (Pan-Cancer)
- Potential surrogate for PD-L1 and mutational load in a research setting
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.
The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.
Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.
Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.
PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.
Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.
The nCounter Immune Exhaustion Panel enables researchers to explore the mechanisms behind T cell, B cell, and NK cell exhaustion in diverse contexts, including cancer and infectious disease.
The Immune Exhaustion Panel provides comprehensive coverage of the most relevant immune checkpoints that can potentially be used to modulate the dynamics of the immune response.